Eisenberg

Researchers are evaluating the PHENO4U data platform in patients undergoing Total Knee Arthroplasty (TKA), a common treatment for advanced knee conditions such as degenerative osteoarthritis, rheumatoid arthritis, posttraumatic arthropathy, chronic knee instability, stiffness, and deformity. The study aims to collect and analyze implant and patient data to identify critical risk factors and improve patient-centered therapies in routine clinical practice. Participants will receive a B. Braun Total Knee Arthroplasty implant and will use the Pheno4U data platform to collect their health data. Patients will also use the BPMpathway sensor and application to measure active range of motion (ROM) and support pre- and postoperative training. Health status questionnaires will be completed throughout the study. Participants will be followed for up to 12 months postoperatively, during which unknown risks or side effects related to TKA will be identified through sensor data and patient apps. Monitoring includes data collection via the Pheno4U platform, usage of the BPMpathway device, and answering health questionnaires to assess outcomes and safety.

Researchers are studying patients who experience delayed or failed healing of bone fractures, a condition affecting about 10-15% of fracture patients and leading to prolonged hospital stays and additional surgeries. This study aims to validate a specific immune cell marker, CD8+ TEMRA cells, as a way to predict which patients may have impaired fracture healing early on. The goal is to improve patient care by identifying those at risk and providing targeted treatments to support their recovery. The study involves collecting blood samples from patients upon hospital arrival to measure their CD8+ TEMRA cell levels before surgery. The healing process is then monitored using X-rays, CT scans, clinical examinations, radiological scores, and patient questionnaires. The first main evaluation of healing will occur 17 to 19 weeks after surgery, with a second evaluation at 34 to 36 weeks to assess for pseudarthrosis or non-union. The biomarker's accuracy will be tested in a blinded manner against the patients' actual healing outcomes. Participants will undergo routine clinical and radiological visits throughout the study. Researchers will assess fracture healing using imaging and functional tests, along with quality of life questionnaires such as the SF-36. The study will track healing progress and compare it to preoperative immune cell levels. The total follow-up extends up to 36 weeks post-surgery, aiming to confirm if CD8+ TEMRA cells can reliably predict delayed or incomplete fracture healing.